CDKN2A and colorectal carcinoma: It has been demonstrated that CDKN2A is silenced in about 30% of CRC (Kohonen-Corish et al., 2014), and hypermethylation of CDKN2A may be correlated with a worse prognosis in CRC patients (Xing et al., 2013).